Pivotal Phase 3 (Part 1) trial demonstrates JEMPERLI plus chemotherapy significantly improved PFS versus chemotherapy plus placebo in patients with...
Media Release SYDNEY, AUSTRALIA, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),...
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors Gamma delta TCRs offer...
REGULATED INFORMATION Appointment to further integrate BioSenic’s both cell therapy and autoimmune disease platforms under the responsibility of a new...
Collaboration allows Hillstream to enter the rapidly growing Immuno-oncology therapeutics market By capitalizing on the long half-life of tumor targeting...
The International Myeloma Foundation will work with Amazon’s cloud computing arm to educate patients, understand donors, increase fundraising, and moreSTUDIO...
ELOX common stock expected to begin trading on a split-adjusted basis on December 2, 2022WATERTOWN, Mass., Dec. 01, 2022 (GLOBE...
GFH009 exhibits robust activity against small cell lung cancer xenografts, both as monotherapy and in combination with PARP inhibitor olaparib...
SAN MATEO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Bluejay Therapeutics announced today that it received approval from the New...
First patient dosed in Phase 1b study of CTX-471 in combination with KEYTRUDA® in cancers of the lung, head and...
Raised $25 million from a Series C financing Proceeds to advance development of first-in-class oncology pipeline across multiple indications DUBLIN,...
NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the...
WALTHAM, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
ROCKVILLE, Md., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage...
Initial CD388 clinical data expected in the first half of 2023SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics,...
Fort Lee, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical...
60% Confirmed Disease Control Rate1 and 7.4 Months Median Time to Tumor Progression for Ewing Sarcoma First-Relapse Patients No Disease...
Funding supports advancement of samuraciclib, an oral CDK7 inhibitor, in combination with endocrine therapy for HR+, HER2- advanced breast cancer...
Acquisition will add distinct new product solution for plastic and reconstructive surgery to address clinical needs and improve patient outcomes...
In-person event and live webcast to follow oral presentation of data from KOMET-001 at ASH in New OrleansSAN DIEGO, Dec....